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The association between air pollution and death and 
hospitalisation due to cardiovascular disease is known. 
What we don’t know is the magnitude of these effects, the 
mechanism and whether or not the relationship is dose 
dependent – does short-term exposure have the same effects 
as long-term exposure? Previous studies looking at long-term 
exposure (estimating exposure over years of follow-up) have 
only evaluated death certificates. What was found was that 
the increase in mortality associated with long-term exposure 
to air pollution is larger than that seen in studies of short-term 
exposure, and long-term effects on death rates serve as the 
current basis for fiercely challenged environmental regulations 
in the USA. 
The authors of this study, recently published in the New 
England Journal of Medicine, evaluated long-term exposure to 
air pollution and the incidence of cardiovascular disease in 
the Women’s Health Initiative (WHI) Observational Study, 
a prospective cohort study with medical-record review and 
classification procedures designed to document specific first 
cardiovascular events. They also examined how between-city 
and within-city gradients of exposure to particulate matter of 
less than 2.5 µm in aerodynamic diameter (PM2.5) are associated 
with first cardiovascular events.  
The WHI enrolled postmenopausal women between the 
ages of 50 and 79 years in the study from 1994 to 1998. The 
authors used data on the monitoring of air pollution from the 
Environmental Protection Agency’s Aerometric Information 
Retrieval System with the use of AirData. Such data are 
recorded for PM2.5 and particulate matter of less than 10 µm in 
aerodynamic diameter (PM10), sulfur dioxide, nitrogen dioxide, 
carbon monoxide, and ozone. They selected monitors on the 
basis of monitoring objectives and scale to represent ambient 
community-scale exposure and excluded those with data 
available from less than 50% of intended samples. The long-
term average PM2.5 concentration was the exposure of interest, 
and the annual average concentration in the year 2000 was the 
primary exposure measure.
Rather than looking at death certificates, this study looked 
at the first cardiovascular event: any of myocardial infarction, 
coronary revascularisation, stroke and death from either 
coronary heart disease or cerebrovascular disease. A total of 
1 816 women, out of 65 893 women included in the study, 
had one or more fatal or nonfatal cardiovascular events, as 
confirmed by a review of medical records, including death from 
coronary heart disease or cerebrovascular disease, coronary 
revascularisation, myocardial infarction, and stroke. In 2000, 
levels of PM2.5 exposure varied from 3.4 to 28.3 µg per cubic 
meter. Each increase of 10 µg per cubic meter was associated 
with a 24% increase in the risk of a cardiovascular event 
and a 76% increase in the risk of death from cardiovascular 
disease. For cardiovascular events, the between-city effect 
appeared to be smaller than the within-city effect. The risk 
of cerebrovascular events was also associated with increased 
levels of PM2.5. 
The conclusion was that the incidence of cardiovascular 
disease and death among postmenopausal women is associated 
with long-term exposure to fine particulate air pollution. This 
study took place in the USA, admittedly not one of the greenest 
countries in the world. But if we consider the amount of fine 
particulate matter in the air of cities in the developing world, 
how much more cardiovascular disease must be present among 
older women in these countries.
Miller KA et al. NEJM 2007; 356: 447-458.
Erythropoietin and target haemoglobin 
concentrations
As someone interested in cycling I have often heard of 
erythropoietin (EPO) used to improve endurance performance 
among the world’s elite cyclists – sometimes with untoward 
results, such as heart attack, stroke and even premature death. 
Now, a recent paper in The Lancet suggests that assiduous 
targeting of higher haemoglobin levels in anaemic patients with 
chronic kidney disease may also cause adverse events.
The authors did a meta-analysis of randomised controlled 
clinical trials, using trials that assessed the effects of targeting 
different haemoglobin concentration in patients with anaemia 
caused by chronic disease who were randomly assigned to 
treatment with recombinant EPO. They found 9 trials that 
enrolled 5 143 patients. There was a significantly higher risk 
of all-cause mortality and arteriovenous access thrombosis 
in the higher haemoglobin target group than in the lower 
haemoglobin target group. There was also a significantly 
higher risk of poorly controlled blood pressure in the higher 
haemoglobin group. The incidence of myocardial infarction was 
much the same in both groups.
The author’s suggestion is that targeting higher haemoglobin 
concentrations when treating patients with anaemia caused by 
chronic kidney disease using EPO puts the patients at increased 
risk of death. Current guidelines do not include an upper limit 
for target haemoglobin concentration and they suggest that this 
should be considered in future recommendations. Cyclists and 
other endurance athletes should also beware.
Phrommintikul A et al. Lancet 2007; 369: 381-388.
Bridget Farham
MIXED BAG




Professor Ariel Jorge Reyes y Garcia, a friend of academic 
medicine in South Africa, died in Montevideo, Uruguay in 
August 2006, shortly after his 63rd birthday. His involvement 
in original research at the University of Natal Medical School 
between 1979 and 1991 did much to bring that institution to the 
attention of colleagues in the Americas and the Latin countries 
of Europe.
Ariel Reyes was a product of the Uruguayan professional 
classes; cultured, a devout scientist, well-informed, widely 
read, competent in at least four European languages and at 
home in many great cities. Trained at the Universidad de la 
Republica, Montevideo, he spent his first postgraduate years 
in the Department of Physiology. He refined his vocational 
training in the Cardiology Department of Leeds, directed by the 
late Stanley Taylor, who considered Reyes to be his brightest 
research and clinical fellow. His best work was performed in 
cooperation with Fundación Procardias in Montevideo and 
during visits to the Department of Clinical and Experimental 
Pharmacology at the University of Natal,  South Africa.
The perceived unimportance of South America to people in 
the Anglophone and central European countries meant that the 
value of his original contributions to medical science was not 
immediately recognised.  During the last three decades Reyes 
published more than 200 papers and delivered innumerable 
lectures, many in collaboration with his friend Professor Perry 
Leary, initially in Natal and Montevideo and later in Ireland 
and Uruguay.  He coordinated outstanding clinical research 
in hypertension and congestive heart failure in Germany 
and Italy with Guiseppe Crippa, and contributed to the 
theoretical and practical development of new drugs, including 
torasemide and nolomirole.  His mastery of statistics, an 
uncommon endowment among clinical investigators, enabled 
him to participate in the design and analyses of the studies he 
coordinated or carried out personally. 
Reyes was unafraid of criticism. A number of published 
papers first provoked heated debate but subsequently became 
incorporated in accepted therapeutic wisdom, usually with 
minimal reference to him and his collaborators. He was among 
the earliest investigators to postulate (and demonstrate) that 
ACE inhibitors could be effective in lowering 24-hour blood 
pressure when administered once daily, irrespective of plasma 
kinetics. He applied mathematical models to the urinary flows 
of water and solutes after the dosing of placebo or diuretics 
to healthy volunteers and identified rational modifications of 
diuretic use in patients. A mathematical model was also fitted 
to data from treated and untreated hypertensives, proving 
that whereas the rate at which a drug lowers blood pressure, 
over time, depends on the drug class and the dose given, the 
final effect over 10-12 weeks tends to be much the same.  He 
and his colleagues proved the concept that sub-diuretic doses 
of common diuretics exist; these doses gradually reduce 
raised blood pressure over a period of weeks with little or 
no disruption of fluid or electrolyte balance. The absence of 
mathematical literacy among the medical profession meant 
that these proofs of clinical theories did not receive the acclaim 
they deserved.  The scientific community is indebted to him, 
inter alia, for the changes he promoted in diuretic use, saving 
many hypertensive patients from the untoward consequences 
of electrolyte imbalances caused by unnecessary use of high 
diuretic doses.
Reyes was motivated by strong principles of scientific 
honesty and was not diplomatic in dealing with simpler 
individuals or with those who did not share his enthusiasms.  
Many of his ideas would remain incomprehensible to 
colleagues and to a pharmaceutical industry that failed to 
appreciate how much could be gained by employing his 
expertise during the early phases of drug development. 
The exception was his contribution to the development of 
torasemide.  He remained an independent voice to the end, 
quite uncorrupted by financial inducements.
Reyes was an active member of numerous committees that 
organised international meetings in both the Americas and in 
Europe and a key figure in at least one South African congress.  
He also served on the editorial boards of various important 
English and Spanish journals.  Ever present at international 
congresses, Reyes was not active as a lecturer, much preferring 
to question speakers from the chair or the floor and extracting 
full value from informal discussions in coffee houses that he 
would rapidly pollute with cigarette smoke. 
Xenophobic by instinct and intensely proud of his own 
cultural roots, he befriended and respected anyone scientifically 
reliable within his chosen academic and research fields.  Ariel 
Reyes could be a difficult person to walk beside; highly 
intelligent, complicated, lucid and amusing, a loyal friend, 
he was also demanding of his family, colleagues and, with 
fatal consequences, himself. He drove himself in pursuit of 
only the best academic and scientific standards, such that his 
personal life was less than ideal and his sudden death probably 
inevitable.
His provocative presence will be missed at many future 
gatherings of clinical pharmacologists and cardiologists. His 
contributions to science will be recognised in due course. 
His friends and family, who loved him unconditionally, will 
remember him with great affection always. 
Perry Leary
IN MEMORIAM
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Professor AM (Albert) Coetzee is op 3 Oktober 2006 in die 
ouderdom van 85 jaar in Pretoria oorlede.  
Sy studente en kollegas sal hom onthou as ‘n veelsydige 
mens met ‘n belangstellingsveld en ‘n spektrum van betrokken-
heid wat ver buite die geneeskunde uitgekring het.
Die feit dat hy, benewens sy geneeskundige kwalifikasies, 
ook ‘n gegradueerde myningenieur was, het hom by uit-
stek geskik vir sy taak as professor van bedryfsgeneeskunde 
gemaak.  Hy was ‘n leermeester wat die fyn balans tussen 
teorie en praktyk tot ‘n kuns bemeester het.  Sy samestelling 
en aanbieding van die diplomakursus in bedryfsgeneeskunde 
het hiervan getuig.  Om dit te kon bereik, het hy lektore en 
aanbieders uit ‘n groot aantal verbandhoudende dissiplines 
betrek.  Die praktiese deel van die kursus, aan die hand van 
besoeke aan nywerhede, was wyd en goed gekies.  Alles tussen 
die diepste goudmyn en lugvaartgeneeskunde, het iemand 
eenkeer gesê.  Dan bly dit ‘n mens by dat professor Penalver, ‘n 
Kubaanse boorling verbonde aan die Universiteit van Miami, 
aan ons gesê het dat dit ‘n voorreg is om onder die leiding van 
so ‘n man van wêreldformaat te kon staan.  
Terwyl hy nog Direkteur van Mediese Dienste by Rand Mines 
was, ‘n pos wat hy 15 jaar lank beklee het, was hy by baie ander 
aktiwiteite betrokke.  Die ouer garde sal die reeks praatjies 
onthou wat oor die radio uitgesaai is.  Hy was ook vir baie jare 
aktief betrokke by die SA Rooikruisvereniging.
Ek het hom leer ken as offisier by 5 Veldambulans, SA 
Geneeskundige Diens, waar hy as vrywilliger diens gedoen en 
later met die rang van majoor uitgetree het.  Hy was ook baie 
aktief betrokke by die Voortrekkers en was kommandant van 
die Linden Kommando.
Sy droë humorsin verdien vermelding.  Ek het eenkeer vir 
hom gesê dat dit half ongewoon klink dat hy die AM Coetzee 
gedenklesing aanbied.  Nee, sê hy, toe die jaarlikse lesing inges-
tel is, het hulle gedink hy gaan nie nog ‘n jaar lewe nie, en kyk 
nou net.
Met ‘n laaste taptoe salueer ons een van die stoere grondleg-





Oom Nic, soos ons hom almal 
geken het, is op 26 September 
2006 in Pretoria aan hartver-
saking oorlede. Hy was 89 
jaar oud. 
Vir 30 jaar was hy my beste 
vriend en mentor. As psigiater 
het hy my bipolêre steurnis 
wat my toe lamgelê het, gou 
in beheer gebring en al die 
jare so gehou. Daarvoor kan 
ek hom nie genoeg bedank 
nie. Hy was ‘n meester in sy 
vak.
Oom Nic is op ‘n plaas in die Koster distrik gebore en het in 
Rustenburg skoolgegaan. Hy het aan die Potchefstroomse Uni-
versiteit vir CHO onderwys bestudeer en ‘n paar jaar skoolge-
hou voordat hy sy mediese studies begin het. Op mediese skool 
was hy ‘n paar jaar ouer as sy medestudente, en het as ‘meester’ 
bekend geword.
Hy en sy eerste vrou, Myda, het vyf kinders gehad: Mariette 
(onderwyseres), Johann (ortopeed), Lourika (oogarts), Rosalie 
(dieetkundige, met gastehuise) en Henrico (onderwyser en 
boer). Na Myda se dood is Nic met dr. Stella Salmond getroud, 
en hulle was meer as 30 jaar saam. 
Nic het by verskeie psigiatriese inrigtings gewerk en was 
jare lank in bevel van die inrigting by Sterkfontein. Hy was ‘n 
Christen en altyd nederig en geduldig, en baie gasvry – ‘n mens 
was altyd welkom in hul huis.
Nic is in die Sterkfontein begraafplaas te Krugersdorp be-
grawe.
Frans de Wet
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